Evidence map›Paper›PMID 42074238›Full record

ReviewInternational journal of molecular sciences2026

Exploring the Complexities of TGF-β Signaling in Keloids: Beyond the Classical Smad Pathway.

Jiao Mo, Hui Huang, Baochen Zhu, Ruiheng Liao, Wei Li, Yange Zhang

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiao MoDepartment of Plastic and Burns Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Hui HuangDepartment of Plastic and Burns Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Baochen ZhuDepartment of Plastic and Burns Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Ruiheng LiaoDepartment of Plastic and Burns Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Wei LiDepartment of Plastic and Burns Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.ORCID 0000-0001-7654-3069
Yange ZhangDepartment of Plastic and Burns Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Keloid is a benign skin disease with excessive growth of fibroblasts, characterized by too much abnormal extracellular matrix deposited in the dermis. It is generally believed that transforming growth factor-β (TGF-β) is the core cytokine that causes keloid. Previously, it was thought that its pathogenic effect was mainly attributed to the classical Smad-dependent pathway. It directly shuttles signals to the nucleus to trigger pro-fibrotic gene transcription. However, accumulating evidence now points to the equally vital role of Smad-independent signaling. Unlike the direct nuclear translocation of Smads, these alternative pathways transmit signals through rapid intracellular kinase cascades. They jointly direct the proliferation, migration, anti-apoptosis, fibrogenesis, and chronic inflammation of fibroblasts in keloids. This review attempts to comprehensively clarify the molecular processes regulated by TGF-β through non-Smad pathways (such as MAPK, PI3K/Akt, Rho GTPase, Wnt/β-catenin, JAK/STAT). Translating these non-Smad insights helps to overcome the high recurrence rates of traditional therapies. Targeting these specific molecular hubs through combination and precision therapies serves to reprogram the fibrotic microenvironment.

Indexed as

KeloidSignal TransductionSmad ProteinsTransforming Growth Factor betaAnimalsFibroblastsHumansSmad ProteinsTransforming Growth Factor betafibrosiskeloidnon-Smad signalingtargeted therapyTGF-β

Identifiers

PMID42074238
PMCPMC13116467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.